RedHill Partner Receives $2.9 Million NCI Grant for Multiple Myeloma Therapy Development

RedHill Biopharma said its partner, the University of Oklahoma, received $2.9 million in National Cancer Institute funding for clinical development of a combination of opaganib and CAR T-cell therapy.